Brii Biosciences Ltd
HKEX:2137
Intrinsic Value
Brii Biosciences Ltd. is a holding company, which engages in the research and development of medicines. [ Read More ]
The intrinsic value of one
Brii Biosciences Ltd
stock under the Base Case scenario is
6.85
HKD.
Compared to the current market price of 1.28 HKD,
Brii Biosciences Ltd
is
Undervalued by 81%.
Brii Biosciences Ltd's market capitalization is 933.6m HKD.
Brii Biosciences Ltd stock price is 1.28 HKD.
Brii Biosciences Ltd stock price (1.28 HKD) is 81% less than its Intrinsic Value (6.85 HKD).
Brii Biosciences Ltd. Open DCF Valuation
Brii Biosciences Ltd stock price (1.28 HKD) is 81% less than its Relative Value (6.85 HKD). Open Relative Valuation
Brii Biosciences Ltd has upside potential of 273% compared to the average analyst price target.
Open Wall St Estimates
Brii Biosciences Ltd has positive three-year average ROE (Return on Equity): 12%. The company is efficient at transforming stockholders' equity into net income.
Brii Biosciences Ltd's ROE (Return on Equity) for the past 12 months is negative and is equal to -6%.
Brii Biosciences Ltd's Revenue has dropped by 99% over the past 12 months.
Brii Biosciences Ltd has negative Operating Income for the last twelve months.
Brii Biosciences Ltd has negative Net Income for the last twelve months.
Brii Biosciences Ltd's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -39%.
Brii Biosciences Ltd's Revenue is forecast to grow at a rate of 706% per year over the next 3 years.
Brii Biosciences Ltd has negative Free Cash Flow for the last twelve months.
Brii Biosciences Ltd has negative three-year average ROIC (Return on Invested Capital): -523%. The company is not efficient at using invested capital to generate operating income.
Brii Biosciences Ltd's short-term assets (3B CNY) exceed its short-term liabilties (126m CNY).
Brii Biosciences Ltd's long-term assets (3B CNY) exceed its long-term liabilties (79m CNY).
Brii Biosciences Ltd's D/E (Debt to Equity) is very low and is equal to 0.
Brii Biosciences Ltd's Altman Z-Score is very high and is equal to 13.77.
Brii Biosciences Ltd doesn't generate enough operating income (-184m CNY) to safely cover interest payments on its debt (625k CNY).
Valuation Backtest
Brii Biosciences Ltd
Run backtest to discover the historical profit from buying and selling
Brii Biosciences Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Brii Biosciences Ltd
Balance Sheet Decomposition
Brii Biosciences Ltd
| Current Assets | 2.8B |
| Cash & Short-Term Investments | 2.7B |
| Other Current Assets | 122.1m |
| Non-Current Assets | 415.5m |
| Long-Term Investments | 142.4m |
| PP&E | 5.6m |
| Intangibles | 267.4m |
| Current Liabilities | 125.9m |
| Other Current Liabilities | 125.9m |
| Non-Current Liabilities | -46.7m |
| Other Non-Current Liabilities | -46.7m |
Earnings Waterfall
Brii Biosciences Ltd
|
Revenue
|
617k
CNY
|
|
Operating Expenses
|
-184.5m
CNY
|
|
Operating Income
|
-183.9m
CNY
|
|
Other Expenses
|
9m
CNY
|
|
Net Income
|
-174.8m
CNY
|
Free Cash Flow Analysis
Brii Biosciences Ltd
Profitability Score
Profitability Due Diligence
Brii Biosciences Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Brii Biosciences Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Brii Biosciences Ltd's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Brii Biosciences Ltd's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Brii Biosciences Ltd
According to Wall Street analysts, the average 1-year price target for
Brii Biosciences Ltd
is 4.77 HKD
with a low forecast of 3.38 HKD and a high forecast of 6.3 HKD.
Shareholder Return
Price
Brii Biosciences Ltd
| Average Annual Return | -19.18% |
| Standard Deviation of Annual Returns | 80.74% |
| Max Drawdown | -98% |
| Market Capitalization | 933.6m HKD |
| Shares Outstanding | 727 816 850 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Brii Biosciences Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Brii Biosciences Ltd. is a holding company, which engages in the research and development of medicines. The company is headquartered in Beijing, Beijing and currently employs 113 full-time employees. The company went IPO on 2021-07-13. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The firm is also developing therapies for COVID-19 and other diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one
Brii Biosciences Ltd
stock under the Base Case scenario is
6.85
HKD.
Compared to the current market price of 1.28 HKD,
Brii Biosciences Ltd
is
Undervalued by 81%.
You don't have any saved screeners yet
